autosomal-dominant inheritance pattern with very few cases of autosomal-recessive inheritance reported. Collecting sporadic case samples has been valuable for gene discovery in more common disorders such as schizophrenia 4 , inflammatory bowel disease 5 and type 2 diabetes 6 , and can have profound effects on the success of targeted therapeutic approaches 2, 7, 8 . The most recent ALS genetic discoveries using large massively parallel sequencing data yielded several gene discoveries, including TBK1, TUBA4A, ANXA11, NEK1 and KIF5A [9] [10] [11] [12] [13] , in addition to other risk loci in C21orf2, SCFD1 and MOBP 14 .
Herein, we assembled the largest ALS exome case-control study to date, consisting of 11,703 individuals (3,864 cases and 7,839 controls). We complemented our analysis by leveraging allele frequencies from large external exome sequencing databases in DiscovEHR (>50,000 samples) and a subset of ExAC (>45,000 samples). In our analysis, we observed an excess of rare protein-truncating variants (PTVs) in ALS cases, and these variants primarily resided in genes under strong purifying selection and therefore less likely to tolerate deleterious mutations (constrained genes). Furthermore, through gene burden testing, in which multiple independent variants are harbored in the same gene (therefore implicating that gene in a disease), we confirmed the known association of SOD1, NEK1 and FUS in ALS. Interestingly, we observed multiple, distinct PTVs in DNAJC7 in our cohort and in an independent replication cohort. In our analysis, the signal in DNAJC7 exceeded genome-wide significance, and immunoblotting showed depletion of DNAJC7 in fibroblasts from a patient with ALS carrying the p.Arg156Ter PTV. DNAJC7 is a highly constrained gene and encodes a DNAJ molecular chaperone, which facilitates protein maintenance and quality control, such as folding of newly synthesized polypeptides and clearance of degraded proteins 15 . Dysregulation of these processes can lead to aberrant protein aggregation, which is one of the pathological hallmarks of neurodegenerative diseases.
Results
Patient demographics and dataset overview. We processed our initial dataset of 15,722 samples through a rigorous quality control pipeline using Hail (https://hail.is), which is an open-source, scalable framework for exploring and analyzing genomic data. All samples were screened for the C9orf72 hexanucleotide expansion (G4C2) and positive samples were excluded from our study. We removed samples that had poor sequencing quality, had high levels of sequence contamination, were closely related to one another, had ambiguous sex status or had population outliers per principal component analysis (PCA) (Supplementary Table 1 ; Supplementary  Figs. 1 and 2 ). Our final dataset consisted of 3,864 cases and 7,839 controls for a total of 11,703 samples. Individuals were of European descent with 7,355 (62.8%) and 4,348 (37.2%) of samples classified as males and females, respectively. Of the 3,864 cases, 2,274 (58.9%) and 1,590 (41.1%) samples were classified as males and females, respectively, whereas 5,081 (64.8%) and 2,758 (35.2%) were classified as males and females, respectively, in controls.
Excess of exome-wide rare PTVs. We assessed four models that incorporated different covariates and assessed their stringency and performance by controlling for benign or synonymous variation. Specifically, each model used Firth-based logistic regression and incorporated some or all of the the following covariates: (1) sample sex, (2) PC1-PC10 and either (3) the total exome count (summation of synonymous variants, benign missense variants, damaging missense variants and PTVs) or (4) benign variation (summation of synonymous and benign missense variants). We show the results from the most conservative model (model 3) , which used all the covariates and the total exome count. Using these models, we evaluated the following four classes of allele frequency thresholds: (1) singletons, which are variants present in a single individual in our dataset (allele count (AC) = 1); (2) doubletons, which are present in two individuals in our dataset (AC = 2); (3) ultra-rare singletons, which are singletons in our dataset and are absent in DiscovEHR, a large, independent exome dataset (AC = 1, 0 in DiscovEHR); and (4) rare variants, which have an allele frequency of <0.01% in our dataset (11, 703 samples), in ExAC (non-psychiatric studies, >45,000 samples) and in DiscovEHR (>50,000 samples). For a full explanation of these models and allele frequency thresholds, please see Methods.
Using model 3, we observed a significant enrichment of singleton PTVs in ALS cases relative to controls (odds ratio (OR) = 1.07, P = 5.00 × 10 -7 ), ultra-rare singleton PTVs (OR = 1.08, P = 1.97 × 10 -6 ) and rare PTVs (OR = 1.04, P = 1.77 × 10 -7 ) (Fig. 1) . These values all passed multiple test correction (P < 0.0125). The number of doubletons (AC = 2) was too low to detect any significant enrichment.
When using model 4, in which we restricted benign variation as the final covariate, the PTV signal was further enriched among singletons (OR = 1.12, P < 2 × 10 -16 ), ultra-rare singletons (OR = 1.10, P = 1.53 × 10 -10 ) and rare variants (OR = 1.04, P = 1.47 × 10 -7 ). Interestingly, in this analysis, there was a consistent and a significant enrichment of damaging missense variants that was not observed in the previous analysis (singletons: OR = 1.06, P < 2 × 10 -16 ; ultra-rare singletons: OR = 1.03, P = 6.33 × 10 -5 ; and rare variants: OR = 1.01, P = 3.24 × 10 -3 ).
In our analyses, we use a standard definition of PTVs as frameshift variants, splice acceptor variants, splice donor variants or stop gained variants, which are due to insertions or deletions (indels) or single nucleotide variants (SNVs). Given the known elevated error rate in indels, we divided all PTVs into either SNVs or indels and repeated the exome-wide analysis to eliminate any false-positive signals. The significant signal was present in both SNVs and indels (SNV singletons: OR = 1.05, P = 2.99 × 10 -3 ; indel singletons: OR = 1.10, P = 5.75 × 10 -6 ; SNV ultra-rare singletons: OR = 1.06, P = 4.34 × 10-3; indel ultra-rare singletons: OR = 1.12, P = 1.96 × 10 -5 ); SNV rare variants: OR = 1.03, P = 6.48 × 10 -4 ; and indel rare variants: OR = 1.05, P = 3.30 × 10 -5 ) ( Supplementary Fig. 4 ). This additional quality control test ensured that the PTV signal was driven by both indels and SNVs and unlikely to be a false positive.
Gene set testing: enrichment of rare variants in constrained genes.
To determine whether we could identify the source of the PTV enrichment, we assessed multiple different gene sets. We evaluated the following genes: (1) constrained genes, which are a set of genes under strong purifying selection; (2) genes known to confer risk for ALS; (3) genes associated with clinically overlapping diseases such as other motor neuron diseases (primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy and spinal muscular atrophy) and genes associated with frontotemporal dementia, Parkinson's disease, Pick's disease and Alzheimer's disease; and (4) genes in which their expression is specific to the brain.
Among constrained genes, we observed a significant enrichment of singleton PTVs (OR = 1.23, P = 7.74 × 10 -7 ), ultra-rare singletons (OR = 1.27, P = 5.76 × 10 -8 ) and rare variants (OR = 1.33, P < 2 × 10 -16 ) ( Fig. 2a ; Supplementary Fig. 5a ). We obtained similar results using model 4 ( Supplementary Fig. 5a ). To determine whether the entire signal can be explained by constrained genes, we removed these genes and reconducted the analysis. The significant enrichment signal persisted; however, the effect sizes were attenuated (singleton PTVs: OR = 1.05, P = 3.30 × 10 -4 ); ultra-rare singleton PTVs: OR = 1.05, P = 1.96 × 10 -3 ; and rare PTVs: OR = 1.02, P = 2.93 × 10 -3 ) ( Fig. 2b; Supplementary Fig. 5b ). This enrichment was also observed in model 4 ( Supplementary Fig. 5b ).
Next, we evaluated the potential effects of known ALS genes. We did not include the ALS genes TBK1, NEK1, KIF5A, C21orf2, MOBP or SCFD1, as these genes were discovered using datasets that contained a large subset of the same samples and can generate an amplified signal. The known ALS genes had negligible, nonsignificant effects ( Fig. 3a ; Supplementary Fig. 6 ). When including variants from TBK1, NEK1, KIF5A, C21orf2, MOBP or SCFD1, the negligible signals persisted; therefore, the initial observation of the exomewide PTV enrichment is not driven by known effects of ALS genes and is likely due to other loci.
Although ALS is traditionally considered to be a disease of upper and lower motor neurons, more than 50% of patients with ALS exhibit neuropsychological and cognitive deficits, with up to 30% of patients meeting diagnostic criteria for frontotemporal dementia, and some patients may also exhibit parkinsonism or Parkinson's disease dementia 1, [16] [17] [18] [19] [20] . We tabulated a list of genes associated with other motor neuron diseases, such as primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy and spinal muscular atrophy. We also included genes associated with frontotemporal dementia, Parkinson's disease, Pick's disease and Alzheimer's disease (Supplementary Table 5 ). We did not observe a significant enrichment of variants in any class of variation, which suggests that the initial observation of PTV enrichment is unlikely to be explained by only these genes ( Fig. 3b ; Supplementary Fig. 7 ).
Finally, we tested whether there is a signal in brain-specific genes, as ALS is a neurodegenerative disease with the predominant symptoms affecting the CNS. We extracted a list of genes with specific brain expression, generated using Genotype-Tissue Expression (GTEx), and performed the same burden analysis across. We did not observe any significant differences in PTVs or damaging missense variations in any allele frequency threshold ( Fig. 3c; Supplementary Fig. 8 ).
Single-gene burden analysis replicates previous ALS associations.
To determine whether a single gene is enriched for variation in ALS cases (ALS-associated) or depleted in ALS cases (ALSprotective), we evaluated ultra-rare (AC = 1, absent in DiscovEHR) and rare (minor allele frequency (MAF) of <0.001% in our dataset, DiscovEHR and ExAC) PTVs and damaging missense variants. Within the ultra-rare variant category, no individual gene passed exome-wide significance. However, the top genes were the following known ALS genes: (1) NEK1 (PTVs, OR = 12.21, P = 7.32 × 10 -5 ); (2) OPTN (PTVs, OR = 20.33, P = 1.2 × 10 -4 ); and (3) SOD1 (damaging missense variants, OR = 46.91, P = 5.03 × 10 -6 ) ( Supplementary Fig.  9 ). Within rare PTVs, only NEK1 (OR = 12.8, P = 4.59 × 10 -9 ), passed exome-wide significance; the next top nine most significant genes, which include FUS, a known ALS gene (OR = 26.4, P = 1.29 × 10 -3 ), are displayed in Table 1 and Fig. 4a . Similarly, within damaging missense variants, SOD1 (OR = 87.7, P = 7.5 × 10 -11 ) was the only gene to pass exome-wide significance; the top nine most significant genes are displayed in Table 1 and Fig. 4b . In Supplementary Tables  2 and 3 , we tabulate the results of the single-gene burden analysis for the proposed ALS genes based on the literature, and their OR and P values.
To determine whether we could reproduce the initial signals observed, we included an additional 21,071 controls from ExAC that are of European descent (non-Finnish) and were not part of any psychiatric or brain-related studies to eliminate any sample overlap. We performed the same burden analyses using 3,864 cases and 28,910 controls (7,839 controls within our dataset and 21,071 additional controls). In Tables 1 and 2, the most significant genes that were identified in the initial discovery are displayed and their OR and P values for both the initial discovery cohort (3,864 cases and 7,839 controls) and the secondary analysis (3,864 cases and 28,910 controls) are tabulated. Within PTVs, NEK1 was still the only gene that exceeded exome-wide significance (OR = 6.5, P = 3.03 × 10 -10 ) ( Fig. 4c ). Of the next nine most significant genes in the initial analysis, the only signal that was strengthened was for FUS (OR = 97.4, P = 2.68 × 10 -6 ). This finding suggests that the other genes may not be true positives or will need further evidence to support their association with ALS. Interestingly, the signal in OPTN, a proposed ALS-associated gene, decreased (OR = 6.6, P = 3.0 × 10 -3 to OR = 2.6, P = 6.9 × 10 -3 ); however, this may be explained in part by the observation that OPTN PTVs tend to manifest as a recessive form of ALS, which may not be detected in our burden model. With the additional controls, multiple genes had similar ORs as the discovery analysis, with their respective P values approaching significance (P values ranged from 7.7 × 10 -5 to 1.4 × 10 -3 ). Most notably, the signal in TBK1, a previously proposed ALS gene 9 , strengthened (initial analysis: OR = 22.3, P = 3.9 × 10 -3 ; secondary analysis: OR = 12.5, P = 9.35 × 10 -4 ). Within damaging missense variants, SOD1 was still the only gene that exceeded exome-wide significance (OR = 79.0, P = 6.0 × 10 -18 ); however, the next nine most significant genes no longer approached significance. Similarly, when integrating additional controls, multiple genes approached significance (P values ranged from 1.2 × 10 -4 to 6.2 × 10 -4 ) ( Fig. 4d ).
Loss-of-function variants in DNAJC7 in patients with ALS.
DNAJC7, which is a highly constrained gene (probability of lossof-function intolerant (pLI) = 0.99), had four PTV carriers in cases (n = 3,864) and 0 in controls (n = 7,839) in the discovery analysis (OR = 18.3, P = 0.01), and 0 PTVs in total controls (n = 28,910; OR = 96.1, P = 1.9 × 10 -4 ). While DNAJC7 did not initially exceed genome-wide significance, its high constraint score and role in neurodegeneration as a member of the HSP40 family encouraged us to evaluate additional datasets to determine its loss-of-function mutation frequency.
We surveyed data from the UK Motor Neurone Disease Association (n = 1,135) and The Agnes Ginges Center for Human Neurogenetics at the Hadassah-Hebrew University Medical Center in Israel (n = 96). We observed an additional 4 carriers for a total of 6 distinct PTVs in 8 individuals with ALS (5,095 cases, 28,910 controls; OR = 96.6, P = 2.5 × 10 -7 ) ( Table 2 ). These DNAJC7 variants were extremely rare or completely absent from large population datasets such as gnomAD ( Table 2 ). The DNAJC7 p.Phe163fs variant was observed in the Israeli cohort. As gnomAD does not currently provide variant frequency on individuals of Middle Eastern ethnicity, we screened an additional 3,244 controls from a mixture of Middle Eastern ethnicities for the p.Phe163fs variant and did not observe any carriers, which further demonstrate its rarity in the general population and in an ancestry-matched population. In addition, we also observed 15 rare missense variants in DNAJC7, of which 4 are predicted to exert a damaging effect in 5 ALS cases and 1 in controls ( Table 2) .
We next proceeded to determine whether any of the PTVs in DNAJC7 affect its mRNA or protein levels. Accordingly, we collected total RNA from human fibroblasts derived from healthy controls and a patient with a DNAJC7 PTV (p.Arg156Ter) and performed quantitative PCR with reverse transcription (qRT-PCR) with two different sets of primer pairs to investigate DNAJC7 transcript levels ( Supplementary Fig. 10a,b ). These data indicated that DNAJC7 mRNA abundance is not significantly altered in fibroblasts harboring a DNAJC7 PTV ( Fig. 5a ). We next carried out immunoblot assays on protein lysates from fibroblasts and determined that DNAJC7 protein levels were significantly reduced in the fibroblasts from the patient with ALS ( Fig. 5b ). Although this PTV could potentially yield a 17.5 kDa protein, no evidence for such a product was detected ( Supplementary Fig. 10c ). Together, our findings indicate that the PTVs we identified in DNAJC7 leads to decreased protein levels of this heat-shock protein co-chaperone. 
Discussion
Herein, we assembled the exomes of 3,864 ALS cases and 7,839 controls and observed an exome-wide enrichment of PTVs, which typically result in protein loss-of-function. The abundance of PTVs in ALS cases seemed to be primarily driven by constrained genes, which are under strong purifying selection. When constrained genes were removed from the analysis, the initial exome-wide enrichment of PTVs remained; however, the effect sizes were much smaller, which suggests that while constrained genes may explain much of the observed PTV enrichment, there may be minor residual effects elsewhere in the genome. Accordingly, we examined the effects of ALS-associated genes, but did not observe any significant enrichment. Importantly, a subset of cases was pre-screened for known pathogenic variants in a select number of known ALS genes, and positive cases were eliminated before assembling the dataset. This additional step attenuated the effect size estimates and significance for genes in this gene set.
Acknowledging the phenotypic variability of ALS, we also evaluated the effects of genes implicated in other motor neuron diseases, such as primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy and spinal muscular atrophy, as well as genes associated with frontotemporal dementia, Parkinson's disease, Pick's disease and Alzheimer's disease. We did not observe a significant enrichment in any class of variation, which suggests that the initial observation of excess PTVs does not reside in these genes. Last, the genes implicated in the development of ALS are not specifically expressed in motor neurons nor are they brain specific, despite the specific degree of degeneration of upper and lower motor neurons. Nevertheless, we tested whether the signal in PTVs was concentrated in brain-specific genes, a much larger gene set than ALS genes only. We did not observe any significant enrichment within brain-specific genes.
The single-gene burden analysis identified the most significant genes as SOD1, NEK1 and FUS, which are known ALS genes. No other individual gene passed exome-wide significance within our dataset (3,864 cases and 7,839 controls) or in the additional controls in the secondary analysis (3,864 cases and 28,910 controls). Notably, in the secondary analysis, multiple genes with consistent OR and lower P values than the initial analysis surfaced. Within PTVs, these included GRIN3B, HRCT1, IL3 and DNAJC7. Interestingly, PTVs in GRIN3B and HRCT1 may offer protection against ALS (GRIN3B: OR = 0.05, P = 7.7 × 10 -5 ; HRCT1: OR = 0.05, P = 1.2 × 10 -4 ), while PTVs in IL3 and DNAJC7 may confer risk (IL3: OR = 10.5, P = 1.8 × 10 -4 ; DNAJC7: OR = 67.4, P = 1.9 × 10 -4 ).
In this analysis, DNAJC7 had 4 PTV carriers in 3,864 cases and 0 in 7,839 and 28,910 controls. Moreover, when integrating data from the UK Motor Neurone Disease Association, we observed an additional 4 PTV carriers for a total of 6 distinct PTVs in 8 individuals (initial analysis: P = 0.01; secondary analysis: P = 1.9 × 10 -4 ; replication analysis: P = 2.5 × 10 -7 ). According to the HPA RNAsequencing normal tissues project 21 and the GTEx project 22 , Odds ratios and the counts in cases and controls are shown in brackets, with P values. a Passed exome-wide significance (P < 2.5 × 10 -6 ) in first analysis (3,864 cases and 7,839 controls). b OR direction was maintained in the secondary analysis (3,864 cases and 28,910 controls) and P value was lower. Gene symbols that are in bold have been previously reported in ALS. The results displayed are from a burden analysis using Fisher's exact test and SKAT, with previously defined covariates (sample sex, PC1-PC10 and total exome count). Exome-wide correction for multiple testing was set at P < 2.5 × 10 -6 , which was the 5% type I error rate divided by the number of genes tested.
DNAJC7 is ubiquitously expressed with elevated expression in the brain. DNAJC7 encodes a molecular chaperone, DNAJ heat shock protein family (HSP40) member C7, and like all DNAJ proteins, contains an approximately 70-amino-acid J-domain, which is critical for binding to HSP70 proteins 23 . There are approximately 50 DNAJ proteins, which are also classified as HSP40 proteins, that facilitate protein maintenance and quality control, such as folding of newly synthesized polypeptides and clearance of degraded proteins 15, 24, 25 . Specifically, DNAJ proteins act as co-chaperones for HSP70 proteins by regulating ATPase activity, aiding in polypeptide binding and preventing premature polypeptide folding 25, 26 . Aberrant protein aggregation due to an accumulation of misfolded proteins is one of the pathological hallmarks of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, The top ten genes with their P values are displayed. Genes in red and blue pass or approach exome-wide significance, respectively. The results displayed are from a burden analysis using Fisher's exact test and sequencing kernel association test (SKAT), with previously defined covariates (sample sex, PC1-PC10 and total exome count). Exome-wide correction for multiple testing was set at P < 2.5 × 10 -6 , which was the 5% type I error rate multiplied by the number of genes tested. b, Rare damaging missense variants in the ALS dataset. c, Rare PTVs in ALS cases with an additional 21,071 non-Finnish European controls for a total of 28,910 controls. Genes in blue were the most significant genes in the discovery analysis. Genes in green were the most significant genes in the secondary analysis. d, Rare damaging missense variants in ALS cases and 28,910 controls and the top ten genes with their P values. Asterisks (*) indicate genes that exceeded the significance threshold. Huntington's disease, prion disease and ALS [27] [28] [29] [30] [31] [32] . Heat-shock proteins have a conserved and central role in protein function by aiding in their folding and stabilization and the clearance of misfolded proteins, processes that ultimately diminish protein aggregates and the associated pathologies. However, genetic aberrations or cellular stress, such as exposure to environmental toxins, fluctuations in temperature, chemical stress, cell injury or aging, can influence the dynamics of the protein quality-control network, allowing misfolded proteins to go undetected and thereby triggering neurotoxicity 33, 34 . Furthermore, abnormal expression of HSP70 and DNAJ genes leads to the formation of protein aggregates in models of Alzheimer's disease 35 , Parkinson's disease 36, 37 , Huntington's disease 35, 38 , prion disease 39, 40 and ALS [41] [42] [43] . In light of these studies, elevated heatshock protein expression is thought to be beneficial in preventing or halting neurodegenerative disease progression 44 . For example, overexpression of DNAJB6b and DNAJB8 suppresses toxic protein aggregation 45 , while overexpression of HSP70 in neuroglioma cells decreases the formation of alpha-synuclein fibrils 46 . Within ALS models, overexpression of HSPB8 promotes the clearance of mutant SOD1 (ref. 47 ), and double transgenic mice overexpressing HSP27 and mutated SOD1 exhibit increased survival of spinal motor neurons compared with mice overexpressing a SOD1 mutation only;
however, the neuroprotective effects were not sustained in later stages of the disease 48 . Finally, when DNAJB2, in which mutations can cause autosomal-recessive spinal muscular atrophy, was overexpressed in mice motor neurons that also expressed a SOD1 mutation (p.Gly93Ala), it led to reduced mutant SOD1 aggregation and improved motor neuron survival 49 . In Supplementary Table 4 , additional heat-shock protein genes that have been reported to harbor pathogenic or likely pathogenic mutations in patients with neurodegenerative diseases are tabulated. In summary, we observed a significant exome-wide enrichment of PTVs that seem to primarily reside in constrained genes. Through gene burden tests, we confirmed the known association of the ALS genes SOD1, NEK1 and FUS, and observed multiple PTVs in ALS cases in a highly constrained HSP40 gene, DNAJC7. Our replication of PTVs in DNAJC7 in an independent ALS cohort and our functional validation highlight DNAJC7 loss as a genetic risk factor for ALS.
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Methods
Study overview. The familial ALS (FALS) and the ALS Genetics (ALSGENS) consortia were assembled to aggregate the existing ALS sequencing data in the community to improve the power to discover novel genetic risk factors for ALS. Herein, we describe our approach of assembling the largest ALS exome casecontrol study to date.
Sample acquisition. Blood samples were collected from subjects following appropriate and informed consent in accordance with the Research Ethics Board at each respective recruiting site within the CReATe, FALS and ALSGENS consortia. All samples known to be carriers of the C9orf72 hexanucleotide expansion (G4C2) were excluded from the study. Additionally, before exome sequencing, a subset of the samples (approximately 2,000) were genotyped and screened for known variants in the known ALS genes SOD1, FUS and TARDBP, and were only included in our study if they were found to be negative for the variants tested.
Exome-sequencing data for control and a subset of case samples were downloaded from dbGAP and were not enriched for (but not specifically screened for) ALS or other neurodegenerative disorders. Control samples were matched to case samples with respect to similar capture kits and coverage levels. The ages of the control samples were not provided for all samples, but in general, controls were older than the typical age of onset of ALS. The data are available under the following accession codes: MIGen Exome Sequencing: Ottawa Heart (phs000806. v1.p1); MIGen Exome Sequencing: Leicester UK Heart Study (phs001000.v1.p1); Swedish Schizophrenia Population-Based Case-Control Exome Sequencing (phs000473.v2.p2); Genome-Wide Association Study of Amyotrophic Lateral Sclerosis (phs000101.v5.p1).
No statistical methods were used to predetermine sample sizes, but our sample sizes were similar to those reported in previous publications 9 . Randomization of experimental groups was not applicable to this study. The experimental conditions were determined by each individual's genetics, which are fixed at conception. This reflects a randomization of the alleles inherited from each individual's parents (that is, Mendelian randomization), but it does not involve randomization of experimental parameters. Blinding was not relevant to the study, as this study was composed of cases and controls. Therefore, the analyst needed to know the casecontrol status of every participant. All samples were joint called together and were aligned to the consensus human genome sequence build GRCh37/hg19, and BAM files were processed using BWA Picard. Genotype calling was performed using the Genome Analysis Toolkit's (GATK) HaplotypeCaller and was performed at the Broad Institute as previously described 50, 51 .
Hail software and quality control. We used Hail (https://hail.is), an open-source, scalable framework, for exploring and analyzing genomic data to process the data. All quality control steps were performed using Hail 0.1 ( Supplementary Table 1 ).
Sample quality control and variant quality control.
Samples with a high proportion of chimeric reads (>5%) and high contamination (>5%) were excluded. Samples with poor call rates (<90%), mean depth <10× or mean genotype-quality <65 were also eliminated from further analysis.
For variant quality control, we restricted the data to GENCODE coding regions, independent of capture interval, where both Agilent and Illumina exomes surpassed 10× mean coverage. We restricted the data to 'PASS' variants in GATK's Variant Quality Score Recalibration (VQSR) filter. Individual genotypes were filtered (set to missing) if they did not meet the following criteria: (1) genotype depth (g.DP) 10 or greater; (2) allele balance ≥0.2 in heterozygous sites or ≤0.8 for homozygous reference and homozygous alternate variants; and (3) genotype quality (GQ) >20. Finally, we selected variants with call rate >90% and Hardy-Weinberg equilibrium test P > 1 × 10 -6 . For quality control analysis, see Supplementary Table 1 and Supplementary Fig. 1 .
Sex imputation. We used the X chromosome inbreeding coefficient to impute sample sex. Samples with an X chromosome inbreeding coefficient of >0.8 were classified as males and samples with an X chromosome inbreeding coefficient of <0.4 were classified as females. Samples within <0.8 and >0.4 were classified as having ambiguous sex status, and were therefore excluded from the dataset ( Supplementary Table 1 ).
PCA. PCA was performed using Hail. We used a subset of high-confidence single nucleotide polymorphisms in the exome capture region to calculate the PCs. We used only ancestry-matched cases and controls as indicated by the overlapping population structure. Furthermore, we used samples from 1000 Genomes to determine the general ethnicity of the ALS dataset. The majority of the samples in the ALS dataset were reported to be of European descent, and this was confirmed by PCA with samples from 1000 Genomes ( Supplementary Fig. 2, Supplementary Table 1 ).
Relatedness check.
We included only unrelated individuals (identity by descent proportion <0.2) (Supplementary Table 1 ).
Variant annotation. We annotated protein-coding variants into the following four classes: (1) synonymous; (2) benign missense; (3) damaging missense; and (4) PTVs. Using VEP annotations (v.85) 52 , we classified synonymous variants as "synonymous_variant", "stop_retained_variant" and "incomplete_terminal_ codon_variant". Missense variants were classified as "inframe_deletion", "inframe_ insertion", "missense_variant", "stop_lost", "start_lost" and "protein_altering_ variant". Furthermore, benign missense variants were predicted as "tolerated" and "benign" by PolyPhen-2 and SIFT, respectively, whereas damaging missense variants were predicted as "probably damaging" and "deleterious". Finally, PTVs were classified as "frameshift_variant", "splice_acceptor_variant", "splice_donor_ variant" and "stop_gained".
Allele frequency categorization. Allele frequencies were estimated within our casecontrol sample and from two external exome sequence databases, DiscovEHR and ExAC 53 . DiscovEHR is a publicly available database with >50,000 exomes of participants who may have some health conditions; however, they do not have ALS. ExAC is a mixture of healthy controls and patients with complex disease, and we restricted our dataset to the non-psychiatric subset of ExAC for allele frequency estimation. Of note, many of our controls are present in the ExAC database, so we restricted our analysis to the DiscovEHR cohort to determine ultra-rare singletons. We did not use gnomAD for this analysis, as our cases and our controls have been deposited in this resource.
We classified variant allele frequency using the following criteria: (1) singletons, which are variants present in a single individual in our dataset (AC = 1); (2) doubletons, which are present in two individuals in our dataset (AC = 2); (3) ultra-rare singletons, which are singletons in our dataset and are absent in DiscovEHR (AC = 1, 0 in DiscovEHR); and (4) rare variants, which have a MAF of <0.01% in our dataset (11,703 samples), in ExAC (non-psychiatric studies, >45,000 samples) and in DiscovEHR (>50,000 samples).
Multivariate models used for analysis.
To determine whether an enrichment of a specific class of variation was present in ALS cases versus controls, we ran multiple Firth logistic regression models. The Firth penalization is used in the likelihood model due to the low counts in many tests, and helps minimize the type I error rate when multiple covariates are included in the model 54 . Model 1 predicted ALS case-control status solely from variant count; model 2 incorporated multiple covariates (sample sex and sample population structure from the first ten PCs); model 3 incorporated all covariates used in the second model along with sample total exome count, which is the exome-wide count of variants in the specific frequency class tested. Finally, model 4 was similar to model 3, but instead used the benign variant count as a covariate, which is the exome-wide count of synonymous variants and benign missense variants only, rather than total exome count. Model 3, which we considered to be the most conservative model to represent the dataset, was used as the preferred model for our analysis ( Supplementary Fig. 3 ).
Exome-wide burden. The four Firth logistic regression models above were used to predict case-control status from exome-wide counts of synonymous, missense and PTVs. Given that sequencing errors are more prevalent when calling indels 55, 56 , we divided variants within the PTV category as either SNV-based PTVs or indelbased PTVs due to SNVs or indels, respectively. This ensured that any enrichment observed in PTVs was not solely from indel-based PTVs. Constrained genes (3,488 pLI genes, 1,730 constrained missense genes) . We evaluated whether variation in loss-of-function intolerant genes are associated with ALS using the same approach as described in the exome-wide approach; however, we extracted only high pLI genes from the exome. We obtained the genic pLI intolerance metrics from a previously published dataset 53 (also available online: ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3/functional_gene_ constraint/). For PTVs, we used genes with a pLI value of >0.9. We also evaluated missense constrained genes generated using previous published data 57 . For missense variants, we used genes with a z-score of >3.09. (38 genes) . We also examined exome-wide burden with known ALS genes removed. The list of ALS genes are as follows: TARDBP, DCTN1, ALS2, CHMP2B, ARHGEF28, MATR3, SQSTM1, FIG4, HNRNPA2B1, C9orf72, SIGMAR1, VCP, SETX, OPTN, PRPH, HNRNPA1, DAO, ATXN2, ANG, FUS, PFN1, CENPV, TAF15, GRN, MAPT, PNPLA6, UNC13A, VAPB, SOD1, NEFH, ARPP21 and UBQLN2. We did not remove TBK1, NEK1, KIF5A, C21orf2, MOBP or SCFD1, as these genes were discovered using datasets that contained a large subset of the same samples. We also performed an analysis with all proposed ALS genes. Neurodegenerative disease genes (120 genes). We investigated whether genes associated with other neurodegenerative phenotypes showed enrichment in ALS cases. We included the following motor neuron diseases: primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy and spinal muscular atrophy. We also used genes associated with Parkinson's disease, frontotemporal dementia, Pick's disease and Alzheimer's disease, as patients with ALS can also present with frontotemporal dementia, cognitive impairment or parkinsonism (Supplementary Table 5 ).
Gene sets.

ALS-associated genes
Brain-expressed genes (2,650 genes) . We evaluated whether genes expressed specifically in the brain were enriched for variation in our dataset. For this analysis, we used brain-specific genes generated from a previously published dataset 50 .
Single-gene burden analysis. ALS dataset (3, 864 cases and 7,839 controls) . To determine whether a single gene is enriched or depleted for rare protein-coding variation in ALS cases, we performed a burden analysis using Fisher's exact test and SKAT, with previously defined covariates (sample sex, PC1-PC10 and total exome count). Exome-wide correction for multiple testing was set at P < 2.5 × 10 -6 , which was the 5% type I error rate multiplied by the number of genes tested. We performed the following four different tests in ALS cases and controls: (1) ultrarare PTVs (AC = 1 and absent in DiscovEHR); (2) ultra-rare damaging missense variants (AC = 1 and absent in DiscovEHR); (3) rare PTVs (MAF < 0.001% in the dataset, DiscovEHR and ExAC); and (4) rare damaging missense variants (MAF < 0.001% in the dataset, DiscovEHR and ExAC). (3,864 cases and 28,910 controls) . We also included an additional 21,071 samples from ExAC that are of European descent (non-Finnish) and were not a part of any psychiatric or brain-related studies to eliminate any sample overlap. Furthermore, to mitigate against false discoveries, in addition to passing our quality control filters, we ensured each variant also passed gnomAD (123,136 exomes and 15,496 genomes) quality control filters. We included variants that were either a singleton (AC = 1) in gnomAD or completely absent to ensure we minimized the inclusion of an excess of variants that passed gnomAD quality control that were rare (MAF < 0.001%), yet were still observed in a very high number of individuals and were likely false-positive variants. The additional 21,071 samples allowed us to perform a secondary analysis of the genes that approached significance (P < 2.5 × 10 -6 ) and to determine whether their OR and P values were maintained and exceed statistical significance, respectively. Additionally, we used the 21,071 controls to increase statistical power to detect any gene discoveries not detected in the original dataset. Importantly, we did not perform a joint PCA on the 21,071 non-Finnish European controls and our dataset; therefore, we were unable to completely match the ancestry of our dataset.
ALS dataset and additional controls
Cell acquisition culture and authentication. The fibroblasts used in this study were previously approved by the institutional review boards of Harvard University, Massachusetts General Hospital and Columbia University. Specific point mutations were confirmed by PCR amplification followed by Sanger sequencing. Weekly, cultures were checked for mycoplasma contamination using a MycoAlert kit (Lonza), and none of the cell lines used in this study tested positive. The use of these cells at Harvard University was further approved and determined not to constitute Human Subjects Research by the Committee on the Use of Human Subjects in Research at Harvard University. Human fibroblasts were grown in DMEM (Invitrogen) supplemented with 15% fetal bovine serum (VWR), 10 mM MEM non-essential amino acid (Millipore) and β-mercaptoethanol 55 μM (Invitrogen), and cultured on tissue culture dishes maintained in 5% CO 2 incubators at 37 °C. Fibroblasts were passaged after reaching confluency using trypsin (Invitrogen).
Immunoblot assays. For analysis of DNAJC7 protein expression levels, fibroblasts were lysed in RIPA buffer (150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris buffer, pH 8.0) containing protease and phosphatase inhibitors (Roche) for 20 min on ice, and centrifuged at high speed to remove insoluble components. A total of 500 μl of RIPA buffer per well of a 6-well plate was routinely used, which yielded ~20 μg of total protein as determined by BCA (Thermo Scientific). For immunoblot assays, 1 μg of total protein was separated by SDS-PAGE (Bio-Rad), transferred to polyvinylidenedifluoride membranes (Bio-Rad) and probed with antibodies against DNAJC7 (1:1,000, Abcam, clone EPR13349) and GAPDH (1:1,000, Millipore, clone 6C5). LI-COR software (Image Studios) was used to quantitate protein band signals, and GAPDH levels were used to normalize each sample. Data are from three technical replicates with n = 12 control and 1 patient lines. To analyze the results from this experiment, we used an unpaired t-test, two-sided with a statistical threshold of P < 0.05.
RNA preparation and qRT-PCR.
Total RNA was isolated from fibroblasts using TRIzol (Invitrogen) according to manufacturer's instructions. A total of 500 μl of TRIzol was added per well of the 6-well culture plates. A total of 300-1,000 ng of total RNA was then used to synthesize complementary DNA by reverse transcription according to an iSCRIPT kit (Bio-Rad). qRT-PCR was then performed using SYBR green (Bio-Rad) and an iCycler system (Bio-Rad).
Quantitative levels for all genes assayed were normalized using GAPDH expression. For comparison between control and patient lines, normalized expression is displayed relative to the average of pooled data points from the healthy controls. The following primer sequences (forward, reverse) were used: GAPDH (AATGGT GAAGGTCGGTGTG, GTGGAGTCATACTGGAACATGTAG); DNAJC7 exons 4-6 (CAGTGAGGTTGGATGACAGTT, ACTCTTGTTGTGCCTGAGC); DNAJC7 exons 13-14 (TACTATCCTCTCTGATCCCAAGA, CCTTGTTCTCCAGCTG AGAG). Data are from three technical replicates with n = 12 control and 1 patient lines. To analyze the results from this experiment, we used an unpaired t-test, two-sided with a statistical threshold of P < 0.05.
Data presentation and statistical analysis. In the figure elements, points and lines represent the median and standard deviation, respectively. The plots display the minimum to maximum. Data distribution was assumed to be normal, but this was not formally tested. For the exome-wide and gene-specific test, we built four models that used Firth logistic regression (please refer to "Multivariate models used for analysis" in the Methods). Multiple test correction P < 0.0125 was considered significant. For gene-specific analyses, a multiple test correction P < 2.5 × 10 -6 was considered significant. For the immunoblot and qPCR assays, the statistical analyses were performed using a two-tailed unpaired Student's t-test, with a *P < 0.05 considered as significant using Prism 7 (Graph Pad). A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
The sequencing data discussed in this publication were obtained through dbGaP and are available under the following accession codes: MIGen Exome Sequencing: Ottawa Heart (phs000806.v1.p1); MIGen Exome Sequencing: Leicester UK Heart Study (phs001000.v1.p1); Swedish Schizophrenia Population-Based Case-control Exome Sequencing (phs000473.v2.p2); Genome-Wide Association Study of Amyotrophic Lateral Sclerosis (phs000101.v5.p1). Custom codes and version used are not applicable.
Data analysis
All data analysis was performed using Hail (https://hail.is/) version 0.1 and R (RStudio Version 1.0.143). LI-COR software (Image Studios, version 1.0) was used to quantitate protein band signal.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability Exome sequencing data for control and a subset of case samples were downloaded from dbGAP and were not enriched for (but not specifically screened for) ALS or other neurodegenerative disorders. Control samples were matched to case samples with respect to similar capture kits and coverage levels. The age of control samples was not provided for all samples but in general, controls were older than typical age of onset of ALS. The data are available under the following accession codes: MIGen Exome Sequencing: Ottawa Heart (phs000806.v1.p1); MIGen Exome Sequencing: Leicester UK Heart Study (phs001000.v1.p1); Swedish Schizophrenia Population-Based Case-control Exome Sequencing (phs000473.v2.p2); Genome-Wide Association Study of Amyotrophic Lateral Sclerosis (phs000101.v5.p1).
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Sample size
Sample size was measured based on collecting as many ALS exomes and ethnically matched controls (non-ALS individuals). No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications.
Data exclusions No data were excluded unless specified in the methods section (i.e. duplicated samples, contaminated samples, geographical isolates, related individuals). This is in accord with established practice.
Replication
To replicate our analysis, we used data from the UK Motor Neurone Disease Association (n=1,135). We also used data from The 236 Agnes Ginges Center for Human Neurogenetics at the Hadassah-Hebrew University Medical 237 Center in Israel (ALS cases n=96) and independent screening of an additional 3,244 controls (non-ALS individuals) from a mixture of Middle Eastern ethnicities. Replication was successful and this is outlined in our manuscript.
Randomization All cases were grouped together and all controls were grouped together. Randomization of experimental groups was not applicable to this study. The experimental conditions are determined by each individual's genetics, which are fixed at conception. This reflects a randomization of the alleles inherited from each individual's parents (i.e.mendelian randomization), but it does not involve randomization of experimental parameters.
Blinding
Blinding was not relevant to the study as this study was composed of cases and controls. Therefore, the analyst needed to know the casecontrol status of every participant.
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